2/19
09:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at Barclays PLC.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at Barclays PLC.
2/13
10:11 am
biib
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here's Why [Yahoo! Finance]
Low
Report
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here's Why [Yahoo! Finance]
2/11
05:00 pm
biib
Biogen Announces Board Chair Transition
Low
Report
Biogen Announces Board Chair Transition
2/11
09:19 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $207.00 to $236.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $207.00 to $236.00. They now have an "outperform" rating on the stock.
2/9
03:02 pm
biib
Biogen (NASDAQ:BIIB) was given a new $231.00 price target on by analysts at Wolfe Research.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $231.00 price target on by analysts at Wolfe Research.
2/9
02:11 pm
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2/9
11:43 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Citigroup Inc. from $185.00 to $215.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Citigroup Inc. from $185.00 to $215.00. They now have a "neutral" rating on the stock.
2/9
10:06 am
biib
Biogen (NASDAQ:BIIB) was given a new $230.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Biogen (NASDAQ:BIIB) was given a new $230.00 price target on by analysts at Canaccord Genuity Group Inc..
2/9
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
2/9
08:58 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Truist Financial Corporation from $190.00 to $193.00. They now have a "hold" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Truist Financial Corporation from $190.00 to $193.00. They now have a "hold" rating on the stock.
2/9
08:45 am
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/9
08:05 am
biib
Biogen (NASDAQ:BIIB) was given a new $201.00 price target on by analysts at Tudor Pickering.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $201.00 price target on by analysts at Tudor Pickering.
2/9
08:04 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Piper Sandler from $157.00 to $177.00. They now have a "neutral" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Piper Sandler from $157.00 to $177.00. They now have a "neutral" rating on the stock.
2/9
08:04 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $178.00 to $187.00. They now have a "neutral" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $178.00 to $187.00. They now have a "neutral" rating on the stock.
2/9
07:20 am
biib
Biogen (NASDAQ:BIIB) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
Medium
Report
Biogen (NASDAQ:BIIB) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
2/9
07:20 am
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/9
07:00 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at HC Wainwright from $194.00 to $228.00. They now have a "buy" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at HC Wainwright from $194.00 to $228.00. They now have a "buy" rating on the stock.
2/8
06:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $200.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $200.00 price target on by analysts at Wells Fargo & Company.
2/8
05:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Morgan Stanley.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Morgan Stanley.
2/7
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Stifel Nicolaus from $202.00 to $214.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Stifel Nicolaus from $202.00 to $214.00. They now have a "buy" rating on the stock.
2/6
04:17 pm
biib
Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... [Yahoo! Finance]
Medium
Report
Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... [Yahoo! Finance]
2/6
04:04 pm
biib
Biogen (NASDAQ:BIIB) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Medium
Report
Biogen (NASDAQ:BIIB) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
2/6
06:56 am
biib
Earnings Snapshot: Biogen tops Q4 estimates; initiates FY26 outlook above forecast [Seeking Alpha]
Medium
Report
Earnings Snapshot: Biogen tops Q4 estimates; initiates FY26 outlook above forecast [Seeking Alpha]
2/4
08:29 am
biib
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy [Yahoo! Finance]
Medium
Report
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy [Yahoo! Finance]
2/4
07:30 am
biib
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Medium
Report
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy